Eliem Therapeutics, Inc.ELYMNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-48.72%
↑ 71% above average
Average (22q)
-165.93%
Historical baseline
Range
High:83.79%
Low:-3134.47%
Volatility
-1939.5%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -48.72% |
| Q2 2025 | 58.30% |
| Q1 2025 | -146.92% |
| Q4 2024 | 5.39% |
| Q3 2024 | 83.79% |
| Q2 2024 | -3134.47% |
| Q1 2024 | 53.39% |
| Q4 2023 | 8.24% |
| Q3 2023 | 23.98% |
| Q2 2023 | 75.31% |
| Q1 2023 | -254.14% |
| Q4 2022 | 38.34% |
| Q3 2022 | 37.50% |
| Q2 2022 | -16.68% |
| Q1 2022 | -25.90% |
| Q4 2021 | -9.67% |
| Q3 2021 | -10.28% |
| Q2 2021 | 53.13% |
| Q1 2021 | -25.15% |
| Q4 2020 | -558.24% |
| Q3 2020 | -38.44% |
| Q2 2020 | 14.87% |
| Q1 2020 | 0.00% |